source
- Bristol Myers shows modest revenue rise, Biogen beats forecasts, Regeneron outlook remains uncertainBioPharma Dive highlighted the latest quarterly earnings from three major biotech firms, noting how investors are interpreting the results. Bristol Myers Squibb reported $11.5 billion in revenue f…
- FDA approves Arvinas' PROTAC drug Veppanu for specific metastatic breast cancerU.S. regulators have granted approval for Veppanu, a protein-degrading therapy developed by biotech firm Arvinas, to treat a defined group of patients with metastatic, estrogen-receptor-positive, H…